Fuente: PubMed "essential OR oil extract" J Med Econ. 2025 Dec;28(1):2043-2056. doi: 10.1080/13696998.2025.2587412. Epub 2025 Nov 30.ABSTRACTBACKGROUND: Timely initiation of appropriate major depressive disorder (MDD) therapy is crucial. Medicaid-insured patients with MDD have higher healthcare resource utilization (HRU) and costs than commercially insured patients, making this group essential to study.METHODS: Claims in the MerativeTM MarketScan® Medicaid Database (2016 to 2022) were used to determine all‑cause and mental health (MH)‑related HRU and healthcare costs of US adults with MDD and ≥ 1 pharmacy claim for cariprazine adjunctive to antidepressant treatment. Outcomes were evaluated in patients initiating cariprazine as their first adjunctive therapy and those initiating cariprazine as a subsequent adjunctive therapy (e.g. after another atypical antipsychotic [AA], non-AA, antidepressant treatment combination). HRU and costs were compared with rate ratios (RRs) and mean cost differences between weighted cariprazine adjunctive therapy cohorts.RESULTS: Among 970 Medicaid beneficiaries meeting inclusion criteria, 392 initiated cariprazine as their first adjunctive therapy and 578 initiated it as a subsequent adjunctive therapy. Patients initiating cariprazine first had significantly lower rates of all‑cause emergency department visits (RR [95% CI] = 0.78 [0.66, 0.94], p < .001) and outpatient (OP) visits (0.80 [0.67, 0.92], p = .012) per patient‑year than those initiating cariprazine subsequently. This translated to lower annual all‑cause medical costs (-$2,101 [-$5,096, -$7], p = .048), driven by lower OP costs (-$2,385, [-$5,251, -$492], p = .016) per patient per year. MH‑related HRU and costs were also significantly lower.CONCLUSIONS: Findings from this real‑world study of Medicaid beneficiaries indicate that earlier cariprazine use is associated with potential reduction in the substantial humanistic and economic burden of MDD.PMID:41320566 | DOI:10.1080/13696998.2025.2587412